In mammals, methylation of the 5Ј position of cytosine in the CpG dinucleotide sequence is the only naturally occurring covalent modification of the genome. The enzyme DNA 5-cytosine methyltransferase (DNA MeTase) 1 catalyzes the transfer of a methyl group from S-adenosylmethionine to the 5 position of cytosines residing in the dinucleotide sequence CpG (1) . DNA methylation patterns correlate inversely with gene expression (2) and, therefore, DNA methylation has been suggested to be an epigenetic determinant of gene expression. However, experimental inhibition of the DNA MeTase has relied for the most part on the nucleoside analogs 5-azacytidine (5-aza-C) and 5-azadeoxycytidine (5-aza-CdR) (3) . These nucleoside analogs affect many cellular processes and have been shown to alter cellular differentiation even in organisms that do not bear methylated bases in their genomes (4). 5-Aza-C is mutagenic and causes DNA damage in fission yeast (5) and in Escherichia coli (6) . To exert their biological effects, 5-aza-C and 5-aza-CdR must be incorporated into the DNA where they covalently trap the bulky 190-kDa DNA methyltransferase enzyme onto the DNA (7). The covalent trapping of DNA MeTase to the DNA and not hypomethylation of DNA itself is reported to be the cause of the mutagenic and cytotoxic effects of 5-aza-CdR (7) . Experiments in which the DNA MeTase has been inhibited by genetic means, for example, by targeted disruption of the DNA MeTase gene in mice, resulted in directly opposite effects on gene expression to those observed with 5-aza-CdR treatment (8 -10) . Therefore, 5-aza-C and 5-aza-CdR may alter gene expression by mechanisms unrelated to the inhibition of DNA MeTase; for example, by modifying chromatin structure, as has been suggested (11) (12) (13) . In fact, inhibition of the histone deacetylases, enzymes known to modify chromatin structure, by trichostatin A, has recently been found to reverse methylationdependent transcriptional silencing (14, 15) . This has prompted the suggestion that much of the transcriptional repression seen is due to histone acetylation and has reopened questions on the role of DNA MeTase in transcriptional repression (16) .
In addition to the potential role the DNA MeTase plays in gene expression, it is also implicated in oncogenesis. Elevated levels of DNA MeTase activity have been observed in many cancer cells in vitro (17) and tumors in vivo (18, 19) . Activation of the oncogenic ras signal transduction pathway has been shown to induce DNA MeTase expression (20, 21) . In addition, elevated DNA MeTase levels are required to maintain the phenotype of these ras-transformed cells, suggesting that DNA methyltransferase is an important downstream effector of these pathways (22) . This is supported by the recent finding that increased DNA MeTase levels are required to maintain the phenotype of fibroblasts transformed with the fos oncogene (23) .
Thus, to isolate the role of the DNA MeTase itself in gene expression and cancer and to dissociate it from effects on chromatin structure requires specific DNA MeTase inhibitors that are not incorporated into genomic DNA. To this aim we have developed potent antisense inhibitors capable of specifically reducing cellular DNA MeTase levels and have employed these inhibitors to study the response of cancer cells to reduction of cellular DNA MeTase levels.
EXPERIMENTAL PROCEDURES
Oligonucleotide Treatment of Cells in Culture-Cells were treated with the 4 ϫ 4 hybrid 2Ј-O-methylphosphorothioate antisense oligonucleotides; MG88 sequence (5Ј-AAGCATGAGCACCGTTCTCC-3Ј, where bold nucleotides are 2Ј-O-methyl modified) and MG208 (5Ј-AAC-GATCAGGACCCTTGTCC-3Ј) at doses from 0 (Lipofectin alone) to 80 nM in the presence of Lipofectin (6.25 g/ml). The cells were incubated * The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
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Western Blotting-Whole cell lysates and nuclear extracts were prepared as described (51) . The antibodies used were as follow monoclonal antibodies p16 INK4 and retinoblastoma (Rb) from PharMingen, monoclonal antibody Cip1 (p21 WAF1/CIP1 ) from Transduction Laboratories, affinity purified polyclonal antibodies actin(l-19) from Santa Cruz, and MET TB antibody raised against glutathione S-transferase fusion protein from the first 10-kDa amino terminus site from methyltransferase. Horseradish peroxidase (Sigma) was used as secondary antibody following by ECL (Amersham).
Immunoprecipitation-Proteins (600 -800 g) were incubated with p16 INK4 (C-20) from Santa Cruz according to their specificity, at 4°C for 1 h. Protein G-Sepharose (Amersham Pharmacia Biotech) was added for an additional 30 min. The samples were washed in IP buffer (Triton X-100, 0.5% sodium deoxycholate, 5 mM EDTA, 25 mM Tris-HCl, pH 7.5), eluted in sample buffer ans and loaded onto SDS-polyacrylamide gradient gel (4 -20%). Autoradiographic films were scanned on a HP Scanjet 5P scanner, digital images were imported in Adobe photoshop and figures assembled.
Methylation-specific PCR (MSP) and Bisulfite Genomic SequencingUsing the Oncor p16 detection system, PCR was performed in a total volume of 25 l under the following conditions: 100 ng of bisulfatetreated DNA (Oncor), 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl 2 , 250 M dNTPs, 80 ng of each primers (5Ј-GTAGGTGGGGAG-GAGTTTAGTTT-3Ј sense and 5Ј-TCTAATAACCAACCAACCCCTAA-3Ј antisense) and 1 unit of AmpliTaq Gold (Perkin-Elmer). The denaturation cycle 95°C; 12 min was following to 35 cycles at 95°C; 45 s, 60°C; 45 s, 72°C; 60 s, and an elongation cycle 72°C; 10 min. The PCR product (5 l) was analyzed on 2% agarose gel. The unmethylated (U) and demethylated (D) primers (Oncor) are also used at the same conditions as specific primers. PCR products were subcloned into PCR 2.1 (Invitrogen) and sequenced to determine demethylation of CpG sites in the p16 proximal promoter.
RESULTS AND DISCUSSION
Sequence-specific Reduction of Human DNA MeTase Protein Levels in Cancer Cells by DNA MeTase Antisense Inhibitors-To identify antisense oligodeoxynucleotides capable of inhibiting DNA MeTase gene expression in human tumor cells, 85 phosphorothioate oligodeoxynucleotides (20 bases in length) bearing sequences complementary to the 5Ј and 3Ј regions of the human DNA MeTase mRNA as well as oligonucleotides targeted to intron-exon boundaries were synthesized and screened for antisense activity (Fig. 1A) . Antisense oligodeoxynucleotides have been shown to act through an RNase Hdependent cleavage of the target mRNA (24, 25) , which then following turnover of previously synthesized protein leads to a reduction in target protein. Two DNA MeTase mRNA regions highly sensitive to antisense inhibition were identified in this screen. These potent DNA MeTase antisense inhibitors, MG88 and MG98, are termed second generation antisense molecules because they contain both phosphorothioate backbone modifications as well as a 2Ј-O-methyl modifications to the ribose on the four 3Ј and 5Ј terminal nucleotides. The combination of these chemistries increases stability and potency of the inhibitors, thus allowing very low (nanomolar) concentrations to be used experimentally, thus minimizing nonspecific effects. MG88 and MG98 have IC 50 values of 40 and 45 nM for inhibition of DNA MeTase mRNA, respectively. Both inhibitors demonstrated sequence-dependent inhibition of the DNA MeTase as scrambled and mismatch, control oligodeoxynucleotides of either one had no effect on DNA MeTase levels.
In the experiments presented here we focused on the DNA MeTase antisense inhibitor MG88. Treatment of T24 human bladder cancer cells and A549 human non-small cell lung can- FIG. 1 . A, schematic of DNA methyltransferase gene structure and position of 20-mer phosphorothioate antisense oligonucleotides (filled circles). Oligonucleotides were designed to hybridize to the 5Ј-untranslated region, 3Ј-untranslated region, intron/exon boundaries, and to regions flanking two ATG sequences in the 5Ј of the DNA MeTase gene. The position of two of the most active antisense oligonucleotides (MG88 and MG98) are shown. Not all oligonucleotides tested in the screen are shown. B, inhibition of the human cytosine DNA methyltransferase protein by MG88 treatment. T24 and A549 cells growing in culture were treated with concentrations ranging from 0 nM (Lipofectin alone) to 80 nM of the DNA methyltransferase antisense oligonucleotides MG88 or the control oligonucleotide MG208 which contains six mismatched bases (see "Experimental Procedures" for sequences). Cells were exposed to oligonucleotide for 4 h on the first day and 4 h on day 2, 48 h after the first treatment cells were harvested and whole cell lysates were prepared and analyzed for DNA MeTase protein levels by Western blot with a DNA MeTase-specific antibody. Both T24 and A549 cells show dosedependent inhibition of DNA MeTase protein by MG88. The bottom portion of the Western blots were cut and hybridized separately to an ␣-actin specific antibody to control for specificity of inhibition and protein loading.
cer cells with 0 -80 nM antisense inhibitor MG88, a 20-base second generation chemistry phosphorothioate oligonucleotide targeted to the DNA MeTase 5Ј region for 48 h, produced dose-dependent reduction in DNA MeTase protein levels (Fig.  1B) . Treatment with the mismatch control oligomer MG208 (a 20-base second generation oligonucleotide with the same sequence as MG88 except 6 mismatched bases) or with Lipofectin alone produced no inhibition of DNA MeTase (Fig. 1B) . The non-target protein, ␣-actin, was used as a control for protein loading (Fig. 1B) . Several other human tumor cell lines, including the breast cancer lines MDA-MB231, MCF-7, the lung cancer cell line, H446, and the colon cancer cell lines HCT116, SW48, and LoVo were used to evaluate the activities of MG88 and MG208 with essentially identical results (data not shown).
DNA MeTase Protein Levels Control p16 ink4A expression by Methylation of Its Promoter Region-The cyclin-dependent kinase inhibitor (CDKI) p16
ink4A regulates the transition from G 1 to S-phases of the cell cycle (26) . Inactivation of p16
ink4A is one of the most frequently observed abnormalities in human cancer (26) . Genetic alterations in p16 ink4A , including point mutations (27) (28) (29) and to a greater extent homozygous deletion (30) are often found in tumors. Transcriptional inactivation and associated hypermethylation of the p16 ink4A promoter region have also been observed in virtually all types of cancer (31) (32) (33) (34) . Treatment of cells with toxic doses of 5-aza-CdR can cause demethylation and induction of p16 ink4A mRNA, detectable by reverse transcriptase-PCR, after recovery from the immediate toxic effects of this drug (31, 35, 36) . To investigate the effect of specifically reducing cellular DNA MeTase levels on the expression and methylation status of a silenced p16 ink4A gene, we treated the T24 human bladder cancer cells that contain a hypermethylated and silenced p16 ink4A gene, with the human DNA MeTase inhibitor MG88. Re-expression of p16 ink4A protein was detected after 5 days of treatment with either 40 or 75 nM MG88 (Fig. 2A) . The latency of the reactivation is expected as inhibition of any molecular target (DNA MeTase in this case) by antisense requires first, that the target mRNA levels are reduced and then that turnover of previously synthesized protein is completed, in contrast to small molecule inhibitors of proteins that directly inhibit the target enzyme. In addition, in the absence of any active demethylating activity, demethylation by decreased methylation capacity is a passive process that requires DNA replication. p16
ink4A reactivation was both dosedependent and time-dependent ( Fig. 2A) . Due to the antiproliferative effect of MG88 itself (see Fig. 3C ), p16 ink4A levels were normalized to cell number ( Fig. 2A, graph) . p16 ink4A was not detected in cells treated with either 40 or 75 nM of the mismatch control MG208 or Lipofectin alone ( Fig. 2A) . As expected, cellular DNA MeTase levels were reduced by MG88 but not by MG208 (Fig. 2A, lower panel) .
Reactivation of p16 ink4A by MG88 Causes Accumulation of Hypophosphorylated pRb and Inhibition of Cellular Proliferation-p16
ink4A regulates progression through the G 1 phase of the cell cycle by inhibiting cyclin-dependent kinase CDK4-mediated phosphorylation of pRb such that the hypophosphorylated form of Rb is associated with G 1 /G 0 growth arrest (26) . Reactivation of p16 ink4A by MG88 treatment caused decrease in the phosphorylated forms of pRb, thus increasing the relative abundance of hypophosphorylated form of pRb overphosphorylated forms of pRb, while treatment of cells with either Lipofectin alone or the control MG208 did not alter the phosphorylation of pRb (Fig. 2D ). These results demonstrate that high levels of DNA MeTase in T24 cells actively suppresses p16 ink4A gene expression and that inhibition of DNA MeTase restores functional p16
ink4A expression capable of regulating downstream molecular targets, such as pRb.
It is not known whether the DNA MeTase enzyme targeted by MG88 (Dnmt1) encodes only maintenance DNA methyltransferase activity or de novo methylation activity as well (37) (38) (39) (40) . To determine whether de novo methylation and silencing of the re-expressed p16 ink4A gene occurs when DNA MeTase returns to control levels, treatments were stopped after 10 days and p16 ink4A and DNA MeTase protein levels were determined on days 3, 5, and 7 post-treatment. High dose MG88 treatment (75 nM) reduced cell numbers by inhibition of proliferation and resulted in cell death after day 10 of treatment, therefore analysis of the duration of p16 ink4A expression was restricted to MG88 40 nM treatments. DNA MeTase protein levels increased as expected in the absence of MG88 treatment and returned to control levels between days 5-7 post-treatment (Fig. 2C, middle panel) . p16 ink4A protein expression decreased steadily over the post-treatment period until it was barely detectable at day 7 post-treatment (Fig. 2B, upper panel) . Fig. 2D shows the inverse relationship between DNA MeTase levels and p16 ink4A levels during and after the treatment period. Of note is the fact that loss of p16 ink4A expression begins at day 14 after DNA MeTase has returned to near control levels. This lag suggests that elevated levels of DNA MeTase over several rounds of replication are required to methylate and inactivate p16 ink4A gene expression. That the inactivation and de novo methylation of p16
ink4A observed are coincident with elevated levels of the DNA MeTase (Dnmt1) suggests that it may contribute to de novo methylation activity itself.
To identify changes in the methylation status of the p16 ink4A promoter induced by MG88 treatment we performed MSP (41) and bisulfite genomic sequencing (42) . MSP analysis revealed that demethylation of the p16 ink4A promoter region occurred as early as day 3 of MG88 treatment (Fig. 3A) . Treatment with MG208 or Lipofectin alone had no effect on methylation of the p16 ink4A gene (Fig. 3A) . Employing bisulfite genomic sequencing provided a more detailed dissection of the demethylaltion events at the p16 ink4A promoter. Analysis of several clones for each treatment condition revealed that 15 CpG sites within the p16 ink4A promoter are methylated in untreated T24 cells (Fig.  3B) . Inhibition of the DNA MeTase by MG88 led to demethylation at 5 of 15 CpG sites by day 3 and demethylation at all 15 CpG sites by day 5 of treatment, whereas treatment with the control MG208 had no effect on p16 ink4A methylation status (Fig. 3B) . Three days after cessation of MG88 treatment the p16 ink4A promoter shows significant re-methylation at 13 of 15 sites reflecting either de novo methylation of these sites or a rapid expansion of a less affected population (Fig. 3B) .
To study the effect of specific inhibition of DNA MeTase on cell growth we monitored cellular proliferation rates both during the treatment and post-treatment periods to determine the duration of the effect. During the course of treatment MG88 dramatically inhibited cell proliferation, whereas treatment of cells with the control MG208 caused only minimal growth inhibition relative to Lipofectin-treated cells (Fig. 3C, panel I) . Inhibition of cell proliferation persisted for approximately 1 week post-treatment, consistent with the finding that p16 ink4A expression was maintained until 7 days after the last dose of MG88 (Fig. 2C) . To determine whether the loss of p16 ink4A expression after reactivation by short term treatment with MG88 was due to the proliferation of a less affected (less demethylated) population of cells within the treated population, or to rapid inactivation of p16 ink4A after MG88 withdrawal, we isolated single cell clones after treatment. Several MG88 clones were, in fact, p16 ink4A negative (data not shown), confirming as expected that MG88 treatment produce a mixed population of p16 ink4A positive and negative cells. Isolation and methylation analysis of a MG88-treated p16 ink4A expressing ink4A levels normalized to cell number. B, phosphorylation of Rb protein was determined by Western blot with an antibody recognizing all phosphorylated forms of Rb. Rb phosphorylation in T24 cells was reduced in MG88-treated cells most significantly at the higher dose (75 nM). C, p16 ink4A and DNA MeTase post-treatment levels. p16 ink4A protein levels were determined by Western blot on whole cell lysates 3, 5, and 7 days after treatments were stopped. On day 3 post-treatment, p16
ink4A protein dropped to almost undetectable levels 7 days after MG88 treatment. DNA MeTase protein levels rose in the absence of MG88 and returned to control levels between days 5 and 7 post-treatment. D, graph shows the quantitation of DNA MeTase and p16
ink4A levels during the course of MG88 treatment and post-treatment periods. clone (MG88C4-5) revealed that the p16 ink4A promoter region was completely non-methylated at all CpG sites evaluated even after 30 days in culture post-MG88 treatment (Fig. 3D) . Thus demonstrating that even short-term (5 day) inhibition of the DNA MeTase by MG88 could induce sustained re-expression of a silenced tumor suppressor gene. Clone MG88C4-5 grew very slowly compared with clones isolated after Lipofectin or MG208 treatment (Fig. 3C, panel 2) ; however, after 40 -45 days in culture post-treatment, the growth rate of MG88C4-5 cells increased dramatically (Fig. 3C, panel 2) . Determination of p16 ink4A protein levels in MG88C4-5 cells revealed a significant decrease at this time point (Fig. 3C, inset) . Loss of p16 ink4A expression after prolonged culture in the absence of MG88 treatment suggests that the DNA MeTase targeted (thought to encode maintenance DNA MeTase activity) may have de novo methyltransferase activity and over time can methylate and inactivate previously unmethylated actively expressing genes.
The antiproliferative effect of DNA MeTase inhibition on T24 cells was apparent as early as 48 h after the first treatment (Fig. 3C) , although p16 ink4A expression was only detected after day 5 of treatment ( Fig. 2A) . Thus, p16
ink4A reactivation alone cannot explain the inhibition of proliferation observed.
Rapid Induction of p21 WAF1 by DNA MeTase InhibitionAnother member of the cyclin-dependent kinase inhibitor (CDKI) family p21 WAF1 , inhibits a wide range of cyclin⅐CDK complexes involved in G 1 and S phase progression (43) (44) (45) . Recently it has been observed that an inverse correlation exists between p21 WAF1 and DNA MeTase protein levels in SV40-transformed and nontransformed cells (46) . In addition, p21 WAF1 and the DNA MeTase have recently been shown to compete with each other for binding to proliferating cell nuclear antigen (PCNA) (46) . To investigate whether DNA MeTase and p21 WAF1 protein levels are linked by a regulatory pathway, we determined p21 WAF1 protein levels in untreated T24 cells and in T24 cells in which DNA MeTase levels had been incrementally reduced by MG88 treatment. p21 WAF1 increased directly with the reduction in DNA MeTase (Fig. 4, A  and B) , while neither Lipofectin nor MG208 had an effect on either DNA MeTase or p21 WAF1 levels (Fig. 4, A and B) . DNA MeTase inhibition induced p21 WAF1 in a dose-dependent fashion as early as 24 h after MG88 treatment (Fig. 4B) , consistent with a role for p21 WAF1 in the antiproliferative effect observed (Fig. 3C ). These findings demonstrate that a functional antagonism between DNA MeTase and p21 WAF1 on cellular proliferation exists. Furthermore, these results provide evidence that the DNA MeTase plays a direct role in cancer cell proliferation. It has been argued that DNA MeTase should not be involved in proliferation as embryonic stem cells from mice homozygous for Dnmt1 mutation (DNA MeTase knock out) proliferate normally (47) . However, Dnmt1Ϫ/Ϫ embryonic stem cells die upon differentiation (47), death of these cells, however, can be rescued by the expression of a DNA MeTase isoform expressed from the same Dnmt1 gene (48) . Although Dnmt1Ϫ/Ϫ embryonic stem cells proliferate normally, Dnmt1Ϫ/Ϫ mice die at mid-gestation (49) . Phenotypic and histological analysis of Dnmt1Ϫ/Ϫ embryos revealed reduced cell proliferation and widespread cell death (49) , supporting a role for DNA MeTase in cell proliferation.
To determine if p21 WAF1 was induced at the transcriptional level we performed RNase protection assays on cells treated with 40 nM of either MG88 or MG208 for 24 and 48 h. No increase in p21 WAF1 mRNA was seen in response to this treatment as demonstrated by RNase protection analysis (Fig. 4C) , suggesting that post-translational regulation of the p21 WAF1 protein is involved. Given that p21
WAF1 mRNA levels do not change with and that p21 WAF1 protein levels rise rapidly even with minimal inhibition of the DNA MeTase (Fig. 4, A and B WAF1 induction by MG88 treatment. p21 WAF1 and ␣-actin protein levels were determined in T24 cells treated with concentration of MG88 or MG208 from 0 to 80 nM for 24 h. C, p21 WAF1 mRNA levels in T24 cells treated with 40 nM of either MG88 or MG208 for 24 and 48 h. Total cellular RNA was isolated from cells after the indicated treatment and analyzed for p21 mRNA and mRNA levels of other cell cycle regulators (as indicated) using the human cell cycle-2 (hcc-2) multiprobe RNase protection kit (PharMingen). RNA loading is equal as determined by the signal from the two housekeeping genes L32 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
by forming a complex with PCNA, cyclin D1, and CDK4 (46) . Human DNA MeTase can compete with p21 WAF1 for PCNA binding (46) . This DNA MeTase-PCNA complex is found in transformed cells with high levels of DNA MeTase but not in non-transformed cells and can be disrupted by p21 WAF1 -derived peptides (50) . This competition between DNA MeTase and p21 WAF1 for the same binding site on PCNA may explain the inverse relationship and regulation observed. In such a model, high levels of DNA MeTase, as those observed in cancer cells, would compete and displace p21 WAF1 from its target PCNA, the free p21 WAF1 may be more susceptible to proteolytic degradation than p21 WAF1 in a complex with PCNA and other proteins. Conversely, higher levels of p21 WAF1 would displace DNA MeTase from PCNA and lead to its degradation. Thus the elevated levels of DNA MeTase found in transformed cells may effectively regulate proliferation both by reducing cellular p21 WAF1 levels and by competing directly for the downstream target PCNA.
Our findings demonstrate a direct effect of human DNA MeTase levels on DNA methylation patterns and gene expression, and that high levels of human DNA methyltransferase enzyme in cancer cells affects cell growth by a mechanism involving hypermethylation and transcriptional silencing of tumor suppressor genes (p16 ink4A ) and by an alternate mechanism, most likely mediated by protein-protein interactions, as in the case of p21 WAF1 . In addition, these finding suggest that non-nucleoside, non-incorporating direct inhibitors of the human DNA MeTase enzyme may be of value in the treatment of human cancer.
